Data Monitoring in Clinical Trial: A Practical Perspective ist die erweiterte 2. Auflage des weit verbreiteten und viel beachteten Fachbuchs, das erstmals im Jahr 2002 erschienen ist. Es bietet einen fundierten und aktuellen Ü berblick ü ber Datenkontrollkomitees, deren Einrichtung, Zweck und Zustä ndigkeiten.
- Enthä lt direkt umsetzbare Handreichungen fü r alle, die klinische Studien verwalten und durchfü hren, sowie fü r Mitglieder von Datenkontrollkomitees.
- Liefert Mitgliedern von Behö rden- und Ethikkommissionen Einblicke in die Kontrolle klinischer Daten.
- Diskutiert Themen mit Relevanz fü r diejenigen, die in den USA und in Europa an klinischen Studien arbeiten.
Die praktischen Handlungsansä tze in diesem Buch sind fü r Experten aus dem akademischen Bereich, bei Regierungsstellen und aus der Industrie, vor allem fü r Medizinstatistiker, Kliniker, Koordinatoren von klinischen Studien von Nutzen, ob sie Studien durchfü hren und/oder begleiten. Ebenso relevant ist dieses Praktikerbuch fü r Mitarbeiter bei Regulierungsstellen und im Bereich der Bioethik.
Inhaltsverzeichnis
Preface to the Second Edition xiii
Preface to the First Edition xv
1 Introduction 1
1. 1 Motivation 1
1. 2 History of data monitoring committees in government-sponsored trials 8
1. 3 Data monitoring committees in trials sponsored by the pharmaceutical industry 15
1. 4 Statistical methods for interim monitoring 18
1. 5 When are data monitoring committees needed? 21
1. 6 Models for data monitoring committees 22
1. 7 Where we are today 24
1. 8 Fundamental principles of data monitoring 25
References 27
2 Responsibilities of the Data Monitoring Committee and Motivating Illustrations 35
2. 1 Fundamental charges 36
2. 2 Specific tasks of the data monitoring committee 39
2. 2. 1 Initial review 40
2. 2. 1. 1 Review of the study protocol 40
2. 2. 1. 2 Review of procedures to ensure quality of study conduct 45
2. 2. 2 Evaluating the quality of ongoing study conduct 47
2. 2. 3 Assessing safety and efficacy data 56
2. 2. 3. 1 Termination due to favorable benefit-to-risk 58
2. 2. 3. 2 Termination due to unfavorable benefit-to-risk 63
2. 2. 3. 3 Termination due to inability to answer trial questions 65
2. 2. 3. 4 Continuation of ongoing clinical trials 68
2. 2. 3. 5 Consideration of the overall picture: primary and secondary analyses 72
2. 2. 3. 6 Modifying sample sizes based on ongoing assessment of event rates 76
2. 2. 4 Reviewing the final results 80
2. 3 The data monitoring committee charter 83
References 84
3 Composition of a Data Monitoring Committee 89
3. 1 Introduction 89
3. 2 Required areas of expertise 90
3. 3 Other relevant characteristics of committee members 96
3. 4 Committee size 98
3. 5 Selecting the committee chair 102
3. 6 Responsibility for appointing committee members 102
3. 7 Representation of other study components on the committee 104
3. 8 Preparation for service on a committee 106
References 109
4 Independence of the Data Monitoring Committee: Avoiding Conflicts of Interest 113
4. 1 Introduction 113
4. 2 Rationale for independence 114
4. 3 Financial independence 116
4. 3. 1 Commercial sponsors 117
4. 3. 2 Government sponsors 118
4. 3. 3 Academic investigators 118
4. 4 Intellectual independence 125
4. 5 Emotional conflicts 131
4. 6 Best practices to address challenges to the DMC's independence 132
4. 6. 1 Adequate training/experience in the DMC process 133
4. 6. 2 Indemnification of DMC members 135
4. 6. 3 Maintaining confidentiality of interim data 136
4. 6. 4 Flexibility of procedures 138
4. 6. 5 DMC meeting format 139
4. 6. 6 Creating independent relationships and reducing conflicts of interest 141
4. 6. 7 Adequately informative DMC reports 142
4. 7 Summary 143
References 144
5 Confidentiality Issues Relating to the Data Monitoring Committee 147
5. 1 Rationale 147
5. 2 Limits of confidentiality 159
5. 2. 1 Interim analysis reports 159
5. 2. 2 Access to aggregate data on efficacy and safety outcomes 161
5. 2. 3 Providing access to interim data on a "need-to-know" basis 164
5. 2. 4 Settings and procedures allowing broader unblinding of safety data 166
5. 2. 5 Consequences of unblinding interim data for regulatory review in ongoing trials 168
5. 2. 6 Some illustrations of broader unblinding 175
5. 2. 7 The steering committee and maintaining confidentiality 187
5. 2. 8 Indirect challenges to confidentiality 189
5. 3 The need for the DMC to review unblended data 190
5. 4 Conclusions: consensus regarding confidentiality 195
References 198
6 Data Monitoring Committee Meetings 203
6. 1 Introduction 203
6. 2 Specific objectives and timing of meetings 204
6. 2. 1 Organizational meeting 205
6. 2. 2 Early safety/trial integrity reviews 208
6. 2. 3 Formal interim efficacy analyses 212
6. 2. 4 End-of-trial debriefing 213
6. 3 Preparation of meeting reports 214
6. 3. 1 Currentness of data in the report 217
6. 3. 2 Inclusion of unadjudicated data 220
6. 4 Format for meetings 221
6. 4. 1 The initial closed session 223
6. 4. 2 The open session 224
6. 4. 3 The final closed session 227
6. 4. 4 Various formats for holding the open and closed sessions 227
6. 4. 5 Meeting duration and venue 229
6. 5 DMC meeting minutes and the DMC recommendations 230
6. 5. 1 The DMC recommendations, the open minutes, and the closed minutes 230
6. 5. 2 The level of detail 232
6. 5. 3 The authorship of the minutes and the sign-off by committee members 233
References 235
7 Data Monitoring Committee Interactions with Other Trial Components or Related Groups 237
7. 1 Introduction 238
7. 2 Study sponsors 238
7. 2. 1 Industry sponsors 239
7. 2. 2 Government sponsors 241
7. 3 Study steering committee/principal investigator 243
7. 4 Study investigators 247
7. 5 Trial statisticians and statistical centers 247
7. 5. 1 The independent statistical center 248
7. 5. 2 Ensuring optimal data presentations 253
7. 6 Institutional review boards 253
7. 7 Regulatory agencies 256
7. 8 Study participants and/or advocacy groups 257
7. 9 Other data monitoring committees 259
References 262
8 Statistical, Philosophical, and Ethical Issues in Data Monitoring 265
8. 1 The need for statistical approaches to monitoring accumulating data 266
8. 2 Overview of statistical methods 270
8. 2. 1 Group sequential methods 271
8. 2. 1. 1 Some group sequential boundaries for establishing benefit 273
8. 2. 1. 2 Group sequential alpha spending functions 277
8. 2. 1. 3 Some group sequential boundaries when early results are unfavorable 280
8. 2. 2 Triangular boundaries 284
8. 2. 3 Stochastic curtailment/conditional power 286
8. 2. 4 Bayesian monitoring 290
8. 2. 5 The general approach to sequential stopping boundaries 293
8. 2. 6 Software packages for sequential clinical trial designs 294
8. 2. 7 Adaptive clinical trial designs 294
8. 3 Protocol specification of the monitoring plan 299
8. 4 Other statistical considerations in monitoring trial data 300
8. 4. 1 Primary versus secondary endpoints 300
8. 4. 2 Short-term versus long-term treatment effects 302
8. 4. 3 Results in subgroups 303
8. 4. 4 Taking external information into account 307
8. 4. 5 Evaluating safety in the context of evidence about efficacy: role of boundaries 309
8. 4. 6 Ensuring proper robustness when defining boundaries for establishing benefit 311
8. 5 Ethical considerations 313
8. 5. 1 Early termination philosophies 313
8. 5. 1. 1 Responding to early beneficial trends 314
8. 5. 1. 2 Responding to early unfavorable trends 318
8. 5. 1. 3 Responding to unexpected safety concerns 324
8. 5. 2 Other ethical considerations 325
References 326
9 Determining When a Data Monitoring Committee is Needed 335
9. 1 Introduction 336
9. 2 Typical settings for an independent data monitoring committee 336
9. 3 Other settings in which an independent data monitoring committee may be valuable 339
9. 3. 1 Early trials of high-risk treatments 339
9. 3. 2 Trials in vulnerable populations 340
9. 3. 3 Trials with potentially large public health impact 341
9. 4 An alternative monitoring approach: the internal monitoring committee 342
9. 5 A decision model assessing need for an independent DMC or an internal monitoring committee 346
9. 6 Settings with little need for an independent or internal monitoring committee 351
9. 7 Summary 352
References 353
10 Regulatory Considerations for the Operation of Data Monitoring Committees 355
10. 1 Introduction 356
10. 2 Data monitoring committees in government regulations 356
10. 3 Regulatory guidance 357
10. 3. 1 US Food and Drug Administration 357
10. 3. 2 International regulatory guidance 360
10. 3. 2. 1 European Union 360
10. 3. 2. 2 International Conference on Harmonization 361
10. 3. 2. 3 The World Health Organization 363
10. 4 Regulatory approaches relevant to data monitoring committee operation: the US FDA 364
10. 5 Policies of funding agencies regarding DMC operations 367
10. 5. 1 National Institutes of Health 367
10. 5. 2 Other federal agencies 369
10. 5. 3 Funding agencies outside the US 369
10. 6 Involvement of FDA staff in data monitoring committee deliberations 370
10. 7 Examples of regulatory authority interaction with data monitoring committees 372
References 379
11 Legal Considerations for DMCs 383
11. 1 DMC indemnification 383
11. 1. 1 Motivating examples 385
11. 1. 2 Emergence of DMCs and heightened awareness of their existence 388
11. 1. 3 Further motivation for indemnification to protect the DMC 390
11. 1. 4 Some specific concerns from current experiences with indemnification 392
11. 1. 5 Potential solutions to indemnification issues 394
11. 1. 6 Confidential disclosure agreement (CDA) 397
11. 1. 7 Summary of indemnification, liability, and contracting issues 399
11. 2 Balancing legal and ethical responsibilities: a need for a mediator? 400
11. 2. 1 A case study: the setting of Actimmune in patients with idiopathic pulmonary fibrosis 402
11. 2. 2 IMMUNE response AIDS clinical trial 405
References 406
Appendix A The Data Monitoring Committee Charter 411
Appendix B Performance Standards Document 431
Statistics in Practice 451
Index 455